Early or Delayed Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Hard Dilemma to Solve.
作者信息
De Nunzio Cosimo, Lombardo Riccardo, Cicione Antonio
机构信息
Urology Unit, Ospedale Sant'Andrea, La Sapienza University of Rome, Rome, Italy.
出版信息
Eur Urol Open Sci. 2022 Jun 16;42:17-18. doi: 10.1016/j.euros.2022.05.014. eCollection 2022 Aug.
Abstract
摘要
相似文献
1
Early or Delayed Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Hard Dilemma to Solve.高危非肌层浸润性膀胱癌的早期或延迟根治性膀胱切除术：一个难以解决的困境。
Eur Urol Open Sci. 2022 Jun 16;42:17-18. doi: 10.1016/j.euros.2022.05.014. eCollection 2022 Aug.
2
Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients.根治性膀胱切除术的指南遵循情况显著影响非肌肉浸润性膀胱癌患者的生存结局。
Jpn J Clin Oncol. 2021 Aug 1;51(8):1303-1312. doi: 10.1093/jjco/hyab060.
3
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.日本接受早期根治性膀胱切除术的卡介苗无反应性非肌肉浸润性膀胱癌患者的预后预测。
Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13.
4
The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer.及时行根治性膀胱切除术对高危非肌层浸润性膀胱癌的作用及重要性
Cancer Treat Res. 2018;175:193-214. doi: 10.1007/978-3-319-93339-9_9.
5
Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.定量分析经组织学证实的 T1 非肌肉浸润性膀胱癌患者行早期根治性膀胱切除术的总生存获益。
Clin Genitourin Cancer. 2020 Dec;18(6):e651-e659. doi: 10.1016/j.clgc.2020.03.013. Epub 2020 Mar 31.
6
Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.比较根治性膀胱切除术与三联疗法治疗肌层浸润性膀胱癌老年患者的生存结局和成本。
JAMA Surg. 2018 Oct 1;153(10):881-889. doi: 10.1001/jamasurg.2018.1680.
7
[Radical cystectomy in patients with pathological non-muscle invasive bladder cancer].[病理非肌层浸润性膀胱癌患者的根治性膀胱切除术]
Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Aug 18;48(4):627-631.
8
Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.八旬膀胱癌肌层浸润性癌患者的治疗模式和总生存结局：国家癌症数据库分析。
J Urol. 2018 Feb;199(2):416-423. doi: 10.1016/j.juro.2017.08.086. Epub 2017 Aug 24.
9
Incidental prostate cancer in patients who underwent radical cystectomy for high risk non muscle invasive bladder cancer: Is it clinically significant?接受高危非肌层浸润性膀胱癌根治性膀胱切除术患者的偶发性前列腺癌：具有临床意义吗？
Urologia. 2022 May;89(2):216-220. doi: 10.1177/03915603211019989. Epub 2021 May 25.
10
本文引用的文献
1
Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.根治性膀胱切除术后原发性与复发性高危非肌层浸润性膀胱癌以及原发性与继发性肌层浸润性膀胱癌的比较结果：一项回顾性多中心研究的结果
Eur Urol Open Sci. 2022 Apr 1;39:14-21. doi: 10.1016/j.euros.2022.02.011. eCollection 2022 May.
2
Evaluation of Functional Outcomes and Quality of Life in Elderly Patients (>75 y.o.) Undergoing Minimally Invasive Radical Cystectomy with Single Stoma Ureterocutaneostomy vs. Bricker Intracorporeal Ileal Conduit Urinary Diversion.对年龄大于75岁的老年患者行单孔输尿管皮肤造口术微创根治性膀胱切除术与Bricker体内回肠膀胱尿流改道术的功能结局和生活质量评估。
J Clin Med. 2021 Dec 27;11(1):136. doi: 10.3390/jcm11010136.
3
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.帕博利珠单抗单药治疗卡介苗（BCG）无应答的高风险非肌肉浸润性膀胱癌（KEYNOTE-057）：一项开放标签、单臂、多中心、2 期研究。
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.
4
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.根治性膀胱切除术联合膀胱内卡介苗治疗高危高级别非肌肉浸润性膀胱癌：随机对照 BRAVO-可行性研究结果。
J Clin Oncol. 2021 Jan 20;39(3):202-214. doi: 10.1200/JCO.20.01665. Epub 2020 Dec 17.
5
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.纳武拉非尼基因导管治疗卡介苗无应答性非肌肉浸润性膀胱癌：一项单臂、开放标签、重复剂量临床试验。
Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27.
6
Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index.多中心分析 80 岁以上患者根治性膀胱切除加输尿管皮肤造口术后的术后并发症：衰弱指数的作用。
Clin Genitourin Cancer. 2019 Oct;17(5):402-407. doi: 10.1016/j.clgc.2019.07.002. Epub 2019 Jul 19.
7
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.早期尿路上皮癌的综合转录组分析。
Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.
8
Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study.内脏肥胖可预测接受根治性膀胱切除术的尿路上皮膀胱癌患者的不良病理特征：一项回顾性队列研究。
World J Urol. 2014 Apr;32(2):559-64. doi: 10.1007/s00345-013-1147-7. Epub 2013 Aug 14.
9
Extraperitoneal radical cystectomy and ureterocutaneostomy in octogenarians.80 岁以上患者的腹膜外根治性膀胱切除术和输尿管皮造口术。
Int Urol Nephrol. 2011 Sep;43(3):663-7. doi: 10.1007/s11255-010-9876-7. Epub 2010 Nov 26.
10
The natural history of a T1 bladder cancer: life-long tumour diathesis.
BJU Int. 1999 Dec;84(9):1102-3. doi: 10.1046/j.1464-410x.1999.00370.x.
Zotero 插件